Most of the decisions that shape a British supplement shelf are taken long before anything reaches it, in files nobody outside the trade reads. One of those files is currently open, and it is unusually easy to follow.
The Food Standards Agency has published a consultation on the market authorisation of one traditional food — dried kenari nuts, Canarium indicum L. — on a notification submitted under Article 14 of the novel food regulations, the route reserved for a traditional food from a third country. Per the consultation page, the FSA is seeking views on the proposed terms of authorisation and on any labelling requirements before ministers finalise the decision. It opened on 6 August 2026 and closes at 11:59pm on 2 September 2026.
Nothing has been decided. A proposed term of authorisation is a proposal, and a consultation is not a permission. We are reporting an open file, not an outcome, and we have no view on what the outcome should be.
The word doing the work is “conditions”
An authorisation of this kind is not a simple yes. It arrives with terms attached, and the consultation asks specifically about labelling requirements — which is to say that part of what is being settled is not whether a food may be sold but what its pack will have to tell you when it is. That is the quiet, structural reason British labels say what they say.
Three regimes, routinely confused
It is worth separating them, because the vocabulary overlaps and the consequences do not.
Authorisation as a novel food decides whether an ingredient may lawfully be placed on the market here. A separate framework, the register of authorised nutrition and health claims, decides what may then be said about it — as we have written before, the two are frequently blurred in marketing copy. Licensing of medicines is a third thing entirely and sits with the MHRA. An ingredient can clear the first and have nothing at all available to it under the second.
That distinction is the whole of the point here. Food supplements are governed in Great Britain as food, not as medicines; they are not intended to diagnose, treat, cure or prevent disease, and clearing a market-authorisation file changes none of that. Anyone with a clinical question should put it to a GP or pharmacist rather than to a label.
Why watch a nut
Because the route is the same one that novel supplement ingredients travel, and it is far more legible when the subject is a dried nut than when it is a botanical extract with a marketing department behind it.